Sglt2 Inhibitors Are Associated With Reduced Cardiovascular Disease For Patients With Type 2 Diabetes | Latest News RSS feed

Sglt2 Inhibitors Are Associated With Reduced Cardiovascular Disease For Patients With Type 2 Diabetes - Latest News


John Buse Part 3, SGLT2 Inhibitors Effects On Amputations And Cardiovascular Disease

Here in this data set, reduced ... patient with neuropathy who’s had a prior amputation but has heart failure? And I think an SGLT-2 Inhibitor would be a really great drug.” There is no such resource. ... read more

Expert Consensus Decision Pathway Addresses Changing Paradigm in Managing T2D Patients With ASCVD

The ACC's 2018 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients ... diabetes medications, the GLP-1 receptor agonists and SGLT-2 inhibitors. Reducing ... read more

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

the possibility that SGLT2 inhibitors might be used to prevent heart failure in patients with type 2 diabetes. Results from the 17,000-patient cardiovascular outcomes trial for dapagliflozin, the sodi... read more

Looking for another news?


Circulating Hematopoietic Stem/Progenitor Cells are Associated with Coronary Stenoses in Patients with Coronary Heart Disease

Furthermore, one-SD increases of circulating HSPCs frequency, white blood cell count and neutrophil count were associated with 2.42 ... CHD patients and found that their low levels in circulation inde... read more


Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

New data showed that empagliflozin reduced the risk of cardiovascular ... type 2 diabetes and peripheral artery disease.” Empagliflozin (marketed as Jardiance ®) is an oral, once daily, highly selecti... read more

Facing Heart Disease: A Guide for Psychiatric Clinicians

reduce the risk of developing heart disease. 2 Other medications, such as aspirin (taken daily), are associated with a decreased risk of MI in those diagnosed with CAD. 2 Medications that treat comorb... read more

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo

However the DPP-4 inhibitor drugs were not associated with a reduced risk of mortality compared to people taking placebo or no treatment at all. Furthermore, SGLT-2 inhibitor ... "Patients with type 2 ... read more

AMPK Activator O304 A Novel Potential Treatment for Diabetic Kidney Disease

Globally ~40% of type 2 diabetes ... vascular system to reduce hyperfiltration. SGLT2 inhibitors are recently introduced anti-hyperglycaemic agents that show improved renal outcome in T2D patients wit... read more

New diabetes drug may increase the risk of serious adverse events : study

Patients ... of type 2 diabetes is SGLT2 inhibitors (sodium-glucose cotransporter 2). Use of the drugs has increased sharply during the past few years, especially since clinical trials have shown that ... read more

Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors

In type 2 ... and cardiovascular (CV) events? Included studies compared DPP-4 inhibitors, GLP-1 agonists, or SGLT-2 inhibitors at market-approved doses with control (placebo or no treatment) or each o... read more

Real-world study shows type 2 diabetics treated with SGLT-2 inhibitors experienced less risk of hospitalization for heart failure and death

AstraZeneca (NYSE:AZN) announces the results from an international real-world study, called CVD-REAL, of patients with type 2 diabetes (T2D) who were treated with SGLT-2 inhibitors ... composite endpo... read more

AstraZeneca announces CVD-REAL study of patients with T2D confirms CV benefits associated with SGLT-2 inhibitors

and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines. The results were pres... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us